Rachel M. A. Dang

Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trial

Vinay K. Puduvalli, Carlos E. de Andrea, Analiz Rodriguez, Jeff Liu et autres

us (code pays fourni par la source)

Author Correction: Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trial

Morris D. Groves, Clark C. Chen, Priya Kumthekar, Vinay K. Puduvalli et autres

us (code pays fourni par la source)

Author Correction: Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trial

Farshad Nassiri, Vikas Patil, Leeor Yefet, Olivia Singh et autres

In the version of the article initially published, in the “TME-high” row in Extended Data Fig. 6a, the images for “CD3” and “CD8” were identical. Extended Data Fig. 6a has now been amended with the correct image for “CD8” in the HTML …

ca, us, es, gb (code pays fourni par la source)

ApplyPolygenicScore: An R package for applying polygenic risk score models

Nicole Zeltser, Rachel M. A. Dang, Rupert Hugh-White, Daniel W. Knight et autres

Purpose: A polygenic score (PGS) predicts an individual's genetic predisposition to a complex trait. A PGS is created by estimating the relative contributions of multiple common variants to the overall trait, creating a polygenic risk model (PGM). The PGM is then applied …

us (code pays fourni par la source)

Prostate lineage-specific metabolism governs luminal differentiation and response to antiandrogen treatment

Jenna M. Giafaglione, Preston D. Crowell, Amelie M.L. Delcourt, Takao Hashimoto et autres

Lineage transitions are a central feature of prostate development, tumourigenesis and treatment resistance. While epigenetic changes are well known to drive prostate lineage transitions, it remains unclear how upstream metabolic signalling contributes to the regulation of prostate epithelial identity. To fill this …

us, be, ca (code pays fourni par la source)

CTIM-19. ONCOLYTIC DNX-2401 VIROTHERAPY PLUS PEMBROLIZUMAB IN RECURRENT GLIOBLASTOMA: A PHASE 1/2 TRIAL

Farshad Nassiri, Vikas Patil, Leeor Yefet, Olivia Singh et autres

Abstract Immune-mediated anti-tumoral responses, elicited by oncolytic viruses and augmented with checkpoint inhibition, may be an effective treatment approach for glioblastoma. Here in this multicenter phase 1/2 study we evaluated the combination of intratumoral delivery of oncolytic virus DNX-2401 followed by intravenous …

ca, us, es (code pays fourni par la source)

Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trial

Farshad Nassiri, Vikas S. Patil, Leeor Yefet, Olivia Singh et autres

Immune-mediated anti-tumoral responses, elicited by oncolytic viruses and augmented with checkpoint inhibition, may be an effective treatment approach for glioblastoma. Here in this multicenter phase 1/2 study we evaluated the combination of intratumoral delivery of oncolytic virus DNX-2401 followed by intravenous anti-PD-1 …

ca, us, es, gb (code pays fourni par la source)

Comparison of newer scoring systems with the conventional scoring systems in general intensive care population.

Deven Juneja, Omender Singh, Prashant Nasa, Rachel M. A. Dang

BACKGROUND: The aim of this study was to assess the performance of Acute Physiology and Chronic Health Evaluation (APACHE) IV, Simplified Acute Physiology Score (SAPS) III, and Mortality Probability Model (MPM) III0 and compare these systems to more widely validated prognosis prediction …

in (code pays fourni par la source)

Use of plasma protein fraction in patients with septic shock admitted to the ICU

Deven Juneja, Omender Singh, Prashant Nasa, Yash Tejas Javeri et autres

Certain colloids like albumin and plasma protein fraction (PPF) have been derived from human plasma and they are used as plasma expanders to treat patients with shock. PPF, which more closely resembles plasma in its constituents, contains albumin plus α and β …

in (code pays fourni par la source)

ICU scoring systems: which one to use in patients with sepsis?

Deven Juneja, Omender Singh, Prashant Nasa, Yash Tejas Javeri et autres

Disease-severity scoring systems have been developed for stratification of ICU patients. These systems have been tested and validated in various general medical and surgical ICU patients. However, the validity and efficacy of these systems, especially the newer generation, has not been assessed …

in (code pays fourni par la source)

ICU scoring systems: which one to use in oncology patients?

Deven Juneja, Prashant Nasa, Omender Singh, Rachel M. A. Dang et autres

The aim was to assess the performance of various ICU scoring systems in oncology patients.

in (code pays fourni par la source)